Medical News Today: Advanced liver cancer: Selective internal radiation therapy safer than sorafenib
A phase III trial of selective internal radiation therapy for hepatocellular carcinoma has found the treatment is safer and just as effective as sorafenib. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 25, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Varian, Elekta settle patent dispute
Radiation oncology firm Varian Medical Systems announced it has reached a confidential...Read more on AuntMinnie.comRelated Reading: Elekta nabs Canadian Medical Device License Brazil hospital uses Varian's Calypso system Varian wins Chinese contract Elekta gets FDA clearance for brachytherapy applicator Varian completes Imaging Components spin-off Elekta to support ASTRO safety initiative (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 4, 2017 Category: Radiology Source Type: news

Updated Guideline on Brachytherapy in Prostate Cancer Updated Guideline on Brachytherapy in Prostate Cancer
The American Society of Clinical Oncology and Cancer Care Ontario have issued updated guidelines on brachytherapy for prostate cancer patients. (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - March 30, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Updated Guidelines on Brachytherapy for Prostate Cancer (FREE)
By Joe Elia Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The American Society of Clinical Oncology and Cancer Care Ontario have issued a joint updated guideline on … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 29, 2017 Category: Primary Care Source Type: news

AccuBoost wins trade grant
Women's health firm AccuBoost has been awarded a trade grant from the Massachusetts...Read more on AuntMinnie.comRelated Reading: AccuBoost signs Baptist Memorial Health Care AccuBoost adds Fla. site AccuBoost lands Minn. customer AccuBoost gets Fla. installation AccuBoost points to study in Brachytherapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 28, 2017 Category: Radiology Source Type: news

ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer
(American Society of Clinical Oncology) The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer. The update provides evidence-based recommendations for different patient risk groups, and specifies the most effective forms of brachytherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 28, 2017 Category: Cancer & Oncology Source Type: news

FDA OK's iCAD tomosynthesis software
Computer-aided detection (CAD) developer iCAD said its PowerLook Tomo Detection...Read more on AuntMinnie.comRelated Reading: iCAD hits Xoft milestone iCAD to highlight Xoft clinical results at SABCS iCAD highlights breast cancer studies at RSNA 2016 iCAD taps new CFO iCAD touts brachytherapy research at ASTRO 2016 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 27, 2017 Category: Radiology Source Type: news

IsoRay Announces Final Court Approval of Class Action Settlement
RICHLAND, Wash., March 9, 2017 -- -- (Healthcare Sales & Marketing Network) -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung,... Devices, Oncology, Litigation IsoRay, brachytherapy, radiotherapy, cesium (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 10, 2017 Category: Pharmaceuticals Source Type: news

Court approves IsoRay class-action settlement
Medical isotope developer IsoRay said a federal court has approved the settlement...Read more on AuntMinnie.comRelated Reading: IsoRay agrees to settle shareholder lawsuit IsoRay revenue falls, net loss edges up in Q4 IsoRay touts brain brachytherapy study results IsoRay revenue edges higher, but net loss grows IsoRay taps new VP of sales, marketing (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 10, 2017 Category: Radiology Source Type: news

iCAD hits Xoft milestone
More than 3,000 early-stage breast cancer patients have been treated with intraoperative...Read more on AuntMinnie.comRelated Reading: iCAD to highlight Xoft clinical results at SABCS iCAD highlights breast cancer studies at RSNA 2016 iCAD taps new CFO iCAD touts brachytherapy research at ASTRO 2016 iCAD president resigns (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 9, 2017 Category: Radiology Source Type: news

iCAD Announces More Than 3,000 Early-Stage Breast Cancer Patients Treated with Intraoperative Radiation Therapy Using the Xoft System
NASHUA, N.H. and MIAMI, March 9, 2017 -- (Healthcare Sales & Marketing Network) -- (Booth #T6) - iCAD, Inc. (ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatmen... Devices, Oncology iCAD , Xoft, IORT, radiotherapy, brachytherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 9, 2017 Category: Pharmaceuticals Source Type: news

Study finds single, escalated dose of brachytherapy radiation may be a safe and effective treatment for localized prostate cancer
Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray (Gy) treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 1, 2017 Category: Science Source Type: news

Single dose of brachytherapy may be an effective treatment for localized prostate cancer
(American Society for Radiation Oncology) Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray (Gy) treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 1, 2017 Category: Global & Universal Source Type: news

Elekta wins Health Canada nod for Leksell Gamma Knife Icon SRS system
Elekta (STO:EKTA B) said today it won Health Canada approval for its Leksell Gamma Knife Icon radiosurgery system. The Stockholm, Sweden-based company touted its Leksell Gamma Knife Icon radiosurgery system as the only SRS system designed specifically for targeting brain tissue. The Icon is the 6th generation version of the radiosurgery system from the Elekta. “Robust clinical evidence from more than one million procedures supports Gamma Knife as the most precise SRS platform in the world. Icon was designed with multiple technology upgrades that enable improved work flow and efficiencies. As part of our ong...
Source: Mass Device - February 28, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Radiosurgery Regulatory/Compliance Elekta AB Source Type: news

Elekta nabs Canadian Medical Device License
Health Canada has issued a Medical Device License (MDL) to radiation oncology...Read more on AuntMinnie.comRelated Reading: Elekta gets FDA clearance for brachytherapy applicator Elekta to support ASTRO safety initiative Varian claims favorable ruling in Elekta patent suit Judge finds in favor of Elekta in dispute with Varian Elekta lands large order from India (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 28, 2017 Category: Radiology Source Type: news

Fewer Skin Side Effects With Accelerated Partial Breast Irradiation Fewer Skin Side Effects With Accelerated Partial Breast Irradiation
Accelerated partial breast irradiation (APBI) with interstitial brachytherapy may be an alternative to whole-breast irradiation (WBI) for some patients, according to five-year results from the GEC-ESTRO trial. (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Elekta wins FDA 510(k) clearance for Venezia gynecological brachytherapy applicator
Elekta (STO:EKTA B) said today it won FDA 510(k) clearance for its Venezia applicator for gynecological brachytherapy, now cleared for the treatment of advanced-stage cervical cancer. The company’s Venezia device is designed to facilitate pre-defined, consistent needle placement for interstitial brachytherapy and to allow operating clinicians the ability to access tumors that extend outside of the cervix. “There is overwhelming clinical evidence that modern image-guided brachytherapy is an effective treatment modality for cervical cancer. Advanced stage disease, however, often requires an interstitial tech...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Oncology Regulatory/Compliance Women's Health Elekta AB Source Type: news

Elekta gets FDA clearance for brachytherapy applicator
Radiation oncology vendor Elekta has received 510(k) clearance from the U.S....Read more on AuntMinnie.comRelated Reading: Elekta to support ASTRO safety initiative Varian claims favorable ruling in Elekta patent suit Judge finds in favor of Elekta in dispute with Varian Elekta lands large order from India Elekta highlights ASTRO MR-linac research (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 2, 2017 Category: Radiology Source Type: news

Brachytherapy Plus EBRT for Intermediate-Risk Prostate Cancer Brachytherapy Plus EBRT for Intermediate-Risk Prostate Cancer
Questions persist about the benefits of combination therapy vs brachytherapy alone, despite findings of a new study, says Dr Gerald Chodak.Medscape Urology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - January 24, 2017 Category: Radiology Tags: Urology Commentary Source Type: news

Stockholm County Council, New Karolinska Solna and Elekta Sign Long-term Collaboration Agreement to Advance Cancer Care
STOCKHOLM, Sweden, Dec 30, 2016 -- (Healthcare Sales & Marketing Network) -- Elekta (EKTA-B.ST), Stockholm's County Council and New Karolinska Solna (NKS) have signed a 13-year collaboration agreement which focuses on innovation, joint research, and educa... Devices, Neurosurgery Elekta, radiation therapy, linear accelerator, brachytherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 30, 2016 Category: Pharmaceuticals Source Type: news

Salutaris lands FDA OK for radionuclide brachytherapy
Ophthalmic medical device developer Salutaris Medical Devices has received...Read more on AuntMinnie.com (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 20, 2016 Category: Radiology Source Type: news

National cancer group recommends Sirtex ’ s microspheres for metastatic colorectal cancer
Sirtex Medical (ASX:SRX) said yesterday that the National Comprehensive Cancer Network has recommended the company’s radioactive microspheres in its Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. The NCCN panel uniformly agreed that selective internal radiation therapy with yttrium-90 microspheres is an option for patients with metastatic, chemotherapy resistant colorectal cancer. The recommendation was supported by the More retrospective analysis study, which included 600 patients with colorectal cancer. The data suggested that selective internal radiation therapy using Y-90 m...
Source: Mass Device - December 13, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Sirtex Medical Source Type: news

iCAD to highlight Xoft clinical results at SABCS
Computer-aided detection (CAD) developer iCAD plans to highlight at the upcoming...Read more on AuntMinnie.comRelated Reading: iCAD highlights breast cancer studies at RSNA 2016 iCAD taps new CFO iCAD touts brachytherapy research at ASTRO 2016 iCAD president resigns iCAD shows revenue decline in Q2 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 7, 2016 Category: Radiology Source Type: news

iCAD highlights breast cancer studies at RSNA 2016
Computer-aided detection (CAD) developer iCAD is touting two studies at RSNA...Read more on AuntMinnie.comRelated Reading: iCAD taps new CFO iCAD touts brachytherapy research at ASTRO 2016 iCAD president resigns iCAD shows revenue decline in Q2 iCAD adds to customer base (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 28, 2016 Category: Radiology Source Type: news

AccuBoost points to study in Brachytherapy
Women's health firm AccuBoost is directing attention to a recent study in Brachytherapy...Read more on AuntMinnie.comRelated Reading: AccuBoost unveils new tech at ABS APBI school AccuBoost adds to customer list AccuBoost inks Ga. contract ART wins Fla. contract ART installs AccuBoost in Okla., Va. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 16, 2016 Category: Radiology Source Type: news

Augmenix scores reimbursement code for SpaceOar
Augmenix said today it won a category 1 current procedural terminology reimbursement code from the American Medical Association for periprostatic implantation of biodegradable material, covering its flagship SpaceOAR device. The SpaceOar is designed to separate the prostate from the rectal wall during radiation treatment for prostate cancer, Augmenix said. The device is delivered through a small needle as a liquid, which then solidifies into a soft gel that expands the space between the prostate and rectum during radiotherapy. The substance then liquefies and is absorbed and cleared from the body in the patient&r...
Source: Mass Device - November 9, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Urology Augmenix Inc. Source Type: news

Eckert & Ziegler posts 9-month financial results
Isotope technology firm Eckert & Ziegler has posted financial results for...Read more on AuntMinnie.comRelated Reading: Eckert & Ziegler reports loss in Q4 Eckert & Ziegler to produce pancreatic cancer agent Eckert & Ziegler warns of lower profit in 2013 report Eckert & Ziegler posts modest sales uptick Eckert & Ziegler acquires brachytherapy firm (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 4, 2016 Category: Radiology Source Type: news

Less than half of cervical cancer patients receive standard-of-care treatment
(University of Colorado Anschutz Medical Campus) University of Colorado Cancer Center study shows that only 44 percent of patients in a large, national sample received all three components of standard-of-care treatment for cervical cancer, most often lacking brachytherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2016 Category: Global & Universal Source Type: news

ASTRO: Brachytherapy Boost Tops EBRT for Prostate Ca (CME/CE)
(MedPage Today) -- But use has fallen despite potential benefits (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - October 3, 2016 Category: Endocrinology Source Type: news

Addition of EBT to brachytherapy does not produce superior PFS results
(NRG Oncology) NRG Oncology researchers reported that adding external radiation therapy to standard brachytherapy did not improve progression-free survival for men with intermediate-risk prostate cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 3, 2016 Category: Cancer & Oncology Source Type: news

ASTRO: Brachytherapy Enough for Mid-Risk Prostate Cancer (CME/CE)
(MedPage Today) -- Similar outcomes, fewer side effects vs external beam therapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 30, 2016 Category: Hematology Source Type: news

Brachytherapy Alone for Intermediate-Risk Prostate Cancer Brachytherapy Alone for Intermediate-Risk Prostate Cancer
Patients with favorable intermediate-risk prostate cancer can be treated with radioactive-seed brachytherapy alone and thus be spared additional late toxicity associated with the usually standard delivery of external-beam radiation first.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 29, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

IsoRay settles class action shareholders suit for $3.5m
IsoRay (NYSE:ISR) said it inked a $3.5 million settlement deal related to a class action suit brought against it by shareholders in June. The Richland, Wash.-based company is facing putative class-action lawsuits from investors, accusing the company of making false or misleading statements about a clinical trial of its Cesium 131 brachytherapy seeds designed to treat cancer in a press release released in May. In an SEC filing posted today, IsoRay said it entered the settlement deal against it and its former CEO through which, if it becomes final, the company agrees to pay $3.5 million. The com...
Source: Mass Device - September 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Legal News Oncology IsoRay Source Type: news

IsoRay agrees to settle shareholder lawsuit
Medical isotope developer IsoRay and its former CEO have signed an agreement...Read more on AuntMinnie.comRelated Reading: IsoRay revenue falls, net loss edges up in Q4 IsoRay touts brain brachytherapy study results IsoRay revenue edges higher, but net loss grows IsoRay taps new VP of sales, marketing IsoRay posts mixed Q2 results (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 27, 2016 Category: Radiology Source Type: news

IsoRay, Inc. Enters Into Agreement to Settle Class Action Shareholder Litigation
RICHLAND, Wash., Sept. 27, 2016 ­-- (Healthcare Sales & Marketing Network) -- IsoRay, Inc. ("IsoRay") (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment o... Devices, Oncology, Litigation IsoRay, brachytherapy, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 27, 2016 Category: Pharmaceuticals Source Type: news

iCAD touts brachytherapy research at ASTRO 2016
At the American Society for Radiation Oncology (ASTRO) meeting, iCAD is touting...Read more on AuntMinnie.comRelated Reading: iCAD president resigns iCAD shows revenue decline in Q2 iCAD adds to customer base iCAD integrates with Fuji digital mammo iCAD to launch skin cancer treatment tool for Xoft (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 26, 2016 Category: Radiology Source Type: news

IsoRay revenue falls, net loss edges up in Q4
Medical isotope developer IsoRay Medical saw a decline in fourth-quarter revenue...Read more on AuntMinnie.comRelated Reading: IsoRay touts brain brachytherapy study results IsoRay revenue edges higher, but net loss grows IsoRay taps new VP of sales, marketing IsoRay posts mixed Q2 results IsoRay CEO to retire (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 9, 2016 Category: Radiology Source Type: news

FDA releases June 2016 510(k) clearances
510(K) SUMMARIES OR 510(K) STATEMENTS FOR FINAL DECISIONS RENDERED DURING THE PERIOD June 2016 TOTAL 510(k)s THIS PERIOD 258 TOTAL WITH SUMMARIES 235 TOTAL WITH STATEMENTS 23 DEVICE: ORAL BOND STEINER LABORATORIES 510(k) NO: K142130(Traditional) ATTN: GREGORY G STEINER PHONE NO : 866 3171348 1051 Olsen Street, Building 3611 SE DECISION MADE: 06-JUN-16 Henderson NV 89011 510(k) SUMMARY AVAILABLE FROM FDA DEVICE: QiF Blood and Fluid Warmer Quality in Flow Ltd. 510(k) NO: K150404(Traditional) ATTN: Neta Sherman PHONE NO : 972 54 6600146 3A Bazel St. POB 10159 SE DECISION MA...
Source: Mass Device - August 31, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news

StemCells soars 600% on reverse merger with Israel ’ s Microbot Medical
Shares in StemCells (NSDQ:STEM) initially soared some 600% this week after the company initiated a reverse merger with Microbot Medical, after the failure of a Phase II trial of StemCells’ spinal cord injury treatment. The merger also saw the resignation of CEO Ian Massey, CFO Gregory Schiffman and a trio of board members, as the team led by Microbot chairman & CEO Harel Gadot prepares to take over. Kenneth Stratton was tapped to serve as interim president, effective August 15. The reverse merger sent STEM shares up 602.7% to a $2.60 close August 16, the day the deal was announced; t...
Source: Mass Device - August 19, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Robotics Microbot Medical StemCells Source Type: news

Cianna nets FDA OK for radar system
Brachytherapy firm Cianna Medical has received an additional 510(k) clearance...Read more on AuntMinnie.comRelated Reading: Cianna highlights SAVI Scout results at SBI Cianna advances 2 SAVI Scout studies Cianna nets FDA OK for SAVI Scout Cianna promotes SAVI results at ASCO BCS Cianna touts breast brachy results at ASBrS show (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 18, 2016 Category: Radiology Source Type: news

High-dose radiation therapy as effective as surgery for aggressive prostate cancer
This study was the first of its kind to directly compare outcomes between radiation-based treatments and surgery for patients with cancers that are Gleason score nine or 10 (the highest score possible, which represents the most aggressive form of cancer). BACKGROUND Prostate cancer is the most common form of cancer among men in the United States, with nearly 180,000 new cases expected to be diagnosed in 2016 alone. Therefore, identifying the optimal treatment strategies for this malignancy is particularly important. In the past oncologists suggested that surgery and radiation-based treatments offer equivalent outcomes. How...
Source: UCLA Newsroom: Health Sciences - August 6, 2016 Category: Universities & Medical Training Source Type: news

Medical News Today: Internal radiation therapy: Better response in metastatic colorectal cancer patients
New analysis shows patients with metastatic colorectal cancer treated with radiation therapy show better response than those receiving chemotherapy alone. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 10, 2016 Category: Consumer Health News Tags: Radiology / Nuclear Medicine Source Type: news

C4 touts MRI-guided prostate brachytherapy study
Image-guided technology developer C4 Imaging said that a recent research study...Read more on AuntMinnie.comRelated Reading: C4 raises $1.3M for multimodality marker C4 Imaging nets 510(k) clearance for MRI marker (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 6, 2016 Category: Radiology Source Type: news

Brachytherapy pioneer Haakon Ragde, M.D., chosen as ASTRO 2016 Honorary Member
(American Society for Radiation Oncology) The American Society for Radiation Oncology (ASTRO) has selected Haakon Ragde, M.D., as its 2016 Honorary Member, the highest honor ASTRO bestows on distinguished cancer researchers, scientists and leaders in disciplines other than radiation oncology, radiobiology or radiation physics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 28, 2016 Category: Global & Universal Source Type: news

IsoRay touts brachytherapy brain cancer trial
IsoRay (NYSE:ISR) today released results from a prospective trial of intraoperative brachytherapy using its Cesium-131 brachytherapy seeds, touting that 95% of treated tumors showed no regrowth at the operative site. The study examined the use of the IsoRay’s seeds for treating recurrent aggressive meningiomas by applying seeds embedded in collagen tiles directly to brain tissue after tumor removal. IsoRay called the technique the “GammaTile” approach, but clarified that it is not commercially available. A total of 95% of the treated tumors showed no radiographic evidence of regrowth of the tumor at ...
Source: Mass Device - June 21, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Neurological Radiosurgery IsoRay Source Type: news

IsoRay touts brain brachytherapy study results
Medical isotope developer IsoRay Medical is highlighting findings from a prospective...Read more on AuntMinnie.comRelated Reading: IsoRay revenue edges higher, but net loss grows IsoRay taps new VP of sales, marketing IsoRay posts mixed Q2 results IsoRay reports flat sales IsoRay picks new distributor for Australia, New Zealand (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 21, 2016 Category: Radiology Source Type: news

Recurrent DES Failure: Try Radiation? (CME/CE)
(MedPage Today) -- Brachytherapy associated with 'reasonable' short-term outcomes in study (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 21, 2016 Category: Cardiology Source Type: news

Elekta inks U.S. brachytherapy distro deal with Kobold Medical.
Elekta (STO:EKTA B) said yesterday it inked a distribution deal with Kobold Medical to distribute its brachytherapy applicators within the U.S. Through the deal, Elekta will market and distribute 4 kobold applicators, as well as its prostate template, the company said. “We are pleased to offer our brachytherapy users in the United States these high quality products from Kobold. Adding these solutions to our brachytherapy portfolio will help us better serve the needs of clinical providers,” Elekta North America exec veep Bill Yaeger said in a press release. Included in the distribution deal is Kobold Medica...
Source: Mass Device - June 16, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Distribution Radiosurgery Elekta AB Kobold Medical Source Type: news